Distribution and diagnosis of dirofilariasis and toxocariasis in Australia.

J. Welch,C. Dobson,C. Freeman

DOI: https://doi.org/10.1111/j.1751-0813.1979.tb14707.x

Australian Veterinary Journal

Abstract:

What problem does this paper attempt to address?

Endovascular Thrombectomy with or Without Intravenous Alteplase in Acute Stroke

Pengfei Yang,Yongwei Zhang,Lei Zhang,Yongxin Zhang,Kilian M. Treurniet,Wenhuo Chen,Ya Peng,Hongxing Han,Jiyue Wang,Shouchun Wang,Congguo Yin,Sheng Liu,Peng Wang,Qi Fang,Hongchao Shi,Jianhong Yang,Changming Wen,Conghui Li,Changchun Jiang,Jun Sun,Xincan Yue,Min Lou,Meng Zhang,Hansheng Shu,Dianjing Sun,Hui Liang,Tong Li,Fuqiang Guo,Kaifu Ke,Haicheng Yuan,Guoping Wang,Weimin Yang,Huaizhang Shi,Tianxiao Li,Zifu Li,Pengfei Xing,Ping Zhang,Yu Zhou,Hao Wang,Yi Xu,Qinghai Huang,Tao Wu,Rui Zhao,Qiang Li,Yibin Fang,Laixing Wang,Jianping Lu,Yansheng Li,Jianhui Fu,Xihua Zhong,Yongjun Wang,Longde Wang,Mayank Goyal,Diederik W. J. Dippel,Bo Hong,Benqiang Deng,Yvo B. W. E. M. Roos,Charles B. L. M. Majoie,Jianmin Liu

DOI: https://doi.org/10.1056/nejmoa2001123

IF: 158.5

2020-01-01

New England Journal of Medicine

Abstract:BACKGROUND In acute ischemic stroke, there is uncertainty regarding the benefit and risk of administering intravenous alteplase before endovascular thrombectomy. METHODS We conducted a trial at 41 academic tertiary care centers in China to evaluate endovascular thrombectomy with or without intravenous alteplase in patients with acute ischemic stroke. Patients with acute ischemic stroke from large-vessel occlusion in the anterior circulation were randomly assigned in a 1:1 ratio to undergo endovascular thrombectomy alone (thrombectomy-alone group) or endovascular thrombectomy preceded by intravenous alteplase, at a dose of 0.9 mg per kilogram of body weight, administered within 4.5 hours after symptom onset (combination-therapy group). The primary analysis for noninferiority assessed the between-group difference in the distribution of the modified Rankin scale scores (range, 0 [no symptoms] to 6 [death]) at 90 days on the basis of a lower boundary of the 95% confidence interval of the adjusted common odds ratio equal to or larger than 0.8. We assessed various secondary outcomes, including death and reperfusion of the ischemic area. RESULTS Of 1586 patients screened, 656 were enrolled, with 327 patients assigned to the thrombectomy-alone group and 329 assigned to the combination-therapy group. Endovascular thrombectomy alone was noninferior to combined intravenous alteplase and endovascular thrombectomy with regard to the primary outcome (adjusted common odds ratio, 1.07; 95% confidence interval, 0.81 to 1.40; P = 0.04 for noninferiority) but was associated with lower percentages of patients with successful reperfusion before thrombectomy (2.4% vs. 7.0%) and overall successful reperfusion (79.4% vs. 84.5%). Mortality at 90 days was 17.7% in the thrombectomy-alone group and 18.8% in the combination-therapy group. CONCLUSIONS In Chinese patients with acute ischemic stroke from large-vessel occlusion, endovascular thrombectomy alone was noninferior with regard to functional outcome, within a 20% margin of confidence, to endovascular thrombectomy preceded by intravenous alteplase administered within 4.5 hours after symptom onset. (Funded by the Stroke Prevention Project of the National Health Commission of the People's Republic of China and the Wu Jieping Medical Foundation; DIRECT-MT ClinicalTrials.gov number, NCT03469206.).
Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis

Wansi Zhong,Ying Zhou,Kemeng Zhang,Shenqiang Yan,Jianzhong Sun,Min Lou

DOI: https://doi.org/10.3390/brainsci11070945

IF: 3.333

2021-01-01

Brain Sciences

Abstract:Background: The benefit of alteplase in minor non-disabling acute ischemic stroke (AIS) is unknown. We aimed to explore the clinical efficacy of alteplase-treatment in minor non-disabling stroke in clinical practice. Methods: We used a prospectively collected database of AIS patients who were being assessed for thrombolysis with alteplase. Minor non-disabling AIS was identified as patients with baseline National Institutes of Health Stroke Scale (NIHSS) score ≤ 5 and a score 0 or 1 on each baseline NIHSS score item (items 1a to 1c being 0). Results: A total of 461 patients with minor non-disabling AIS were included and among them 240 (52.1%) patients were treated with alteplase and 113 (24.5%) patients had severe stenosis/occlusion of large vessels. No significant association of 90-day excellent outcome was found with alteplase-treatment (77.1% vs. 80.5%, p 1 = 0.425; OR 0.911, 95% CI 0.428 to 1.940; p 2 = 0.808). However, among patients with severe stenosis/occlusion of large vessels, alteplase-treatment was independently associated with excellent outcome (74.4% vs. 45.7%, p 1 = 0.005; OR 4.709, 95% CI 1.391 to 11.962; p 2 = 0.010). Conclusion: Although alteplase-treatment did not result in an excellent outcome in general minor non-disabling stroke patients, it may work in those specific patients who had severe stenosis/occlusion of large vessels.
Effect of Baseline Infarct Size on Endovascular Thrombectomy with or Without Intravenous Alteplase in Stroke Patients: A Subgroup Analysis of a Randomized Trial (DIRECT-MT).

Zhen Yu Jia,Yong Xin Zhang,Yue Zhou Cao,Lin Bo Zhao,Hai Bin Shi,Lei Zhang,Zi Fu Li,Hong Jian Shen,Min Lou,Yong Wei Zhang,Guo Cong Yin,Xiao Fei Ye,Peng Fei Yang,Sheng Liu,Jian Min Liu

DOI: https://doi.org/10.1111/ene.15276

2022-01-01

European Journal of Neurology

Abstract:Background and purpose DIRECT-MT showed that endovascular thrombectomy was noninferior to thrombectomy preceded by intravenous alteplase with regard to functional outcome in patients with acute ischemic stroke. In this post hoc analysis, we examined whether infarct size modified the effect of alteplase. Methods All patients with baseline Alberta Stroke Program Early Computed Tomography Score (ASPECTS) grades were included. The primary outcome was the 90-day modified Rankin Scale (mRS) score. Multivariate ordinal logistic regression analysis was used to calculate the adjusted common odds ratio (OR) for better functional outcome based on the mRS for thrombectomy alone versus combination therapy. An interaction term was entered to test for an interaction with baseline ASPECTS subgroups: 0-4 versus 5-7 versus 8-10. Results Of 649 patients, 323 (49.8%) were in the thrombectomy-alone group and 326 (50.2%) in the combination-therapy group. There was no significant treatment-by-trichotomized ASPECTS interaction with alteplase prior to endovascular treatment for the primary endpoint of ordinal mRS (p-value interaction term relative to ASPECTS 8-10: ASPECTS 0-4, p = 0.386; ASPECTS 5-7, p = 0.936). Adjusted common ORs for improvement in the 90-day mRS with thrombectomy alone compared with combination therapy were 1.99 (95% confidence interval = 0.72-5.46) for ASPECTS 0-4, 1.07 (0.62-1.86) for ASPECTS 5-7, and 1.03 (0.74-1.45) for ASPECTS 8-10. There was no significant difference in the safety outcomes between the two groups. Conclusions Baseline infarct size may not modify the effect of alteplase prior to endovascular thrombectomy with regard to favorable functional outcomes and adverse events.
Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis

Vignan Yogendrakumar,Leonid Churilov,Prodipta Guha,James Beharry,Peter J. Mitchell,Timothy J. Kleinig,Nawaf Yassi,Vincent Thijs,Teddy Y. Wu,Helen Brown,Helen M. Dewey,Tissa Wijeratne,Bernard Yan,Gagan Sharma,Patricia M. Desmond,Mark W. Parsons,Geoffrey A. Donnan,Stephen M. Davis,Bruce C.V. Campbell,Richard Dowling,Steven Bush,Rebecca Scroop,Mark Brooks,Hamed Asadi,Timothy Ang,Ferdinand Miteff,Christopher Levi,Henry Zhao,Felix Ng,Fana Alemseged,Henry Rice,Laetitia de Villiers,Kendal Redmond,David Leggett

DOI: https://doi.org/10.1161/STROKEAHA.122.041061

IF: 10.17

2023-02-04

Stroke

Abstract:Stroke, Ahead of Print. Background:Intracranial occlusion site, contrast permeability, and clot burden are thrombus characteristics that influence alteplase-associated reperfusion. In this study, we assessed the reperfusion efficacy of tenecteplase and alteplase in subgroups based on these characteristics in a pooled analysis of the EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke).Methods:Patients with large vessel occlusion were randomized to treatment with tenecteplase (0.25 or 0.4 mg/kg) or alteplase before thrombectomy in hospitals across Australia and New Zealand (2015–2019). The primary outcome, early reperfusion, was defined as the absence of retrievable thrombus or >50% reperfusion on first-pass angiogram. We compared the effect of tenecteplase versus alteplase overall, and in subgroups, based on the following measured with computed tomography angiography: intracranial occlusion site, contrast permeability (measured via residual flow grades), and clot burden (measured via clot burden scores). We adjusted for covariates using mixed effects logistic regression models.Results:Tenecteplase was associated with higher odds of early reperfusion (75/369 [20%] versus alteplase: 9/96 [9%], adjusted odds ratio [aOR], 2.18 [95% CI, 1.03–4.63]). The difference between thrombolytics was notable in occlusions with low clot burden (tenecteplase: 66/261 [25%] versus alteplase: 5/67 [7%], aOR, 3.93 [95% CI, 1.50–10.33]) when compared to high clot burden lesions (tenecteplase: 9/108 [8%] versus alteplase: 4/29 [14%], aOR, 0.58 [95% CI, 0.16–2.06];Pinteraction=0.01). We did not observe an association between contrast permeability and tenecteplase treatment effect (permeability present: aOR, 2.83 [95% CI, 1.00–8.05] versus absent: aOR, 1.98 [95% CI, 0.65–6.03];Pinteraction=0.62). Tenecteplase treatment effect was superior with distal M1 or M2 occlusions (53/176 [30%] versus alteplase: 4/42 [10%], aOR, 3.73 [95% CI, 1.25–11.11]), but both thrombolytics had limited efficacy with internal carotid artery occlusions (tenecteplase 1/73 [1%] versus alteplase 1/19 [5%], aOR, 0.22 [95% CI, 0.01–3.83];Pinteraction=0.16).Conclusions:Tenecteplase demonstrates superior early reperfusion versus alteplase in lesions with low clot burden. Reperfusion efficacy remains limited in internal carotid artery occlusions and lesions with high clot burden. Further innovation in thrombolytic therapies are required.

peripheral vascular disease,clinical neurology
Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial

Yu Zhou,Lei Zhang,Johanna Ospel,Mayank Goyal,Rosalie McDonough,Pengfei Xing,Zifu Li,Xiaoxi Zhang,Yongxin Zhang,Yongwei Zhang,Bo Hong,Yi Xu,Qinghai Huang,Qiang Li,Ying Yu,Qiao Zuo,Xiaofei Ye,Pengfei Yang,Jianmin Liu,

DOI: https://doi.org/10.1161/strokeaha.121.037061

IF: 10.17

2022-03-04

Stroke

Abstract:Background: The added value of intravenous alteplase in reperfusing ischemic brain tissue in patients undergoing endovascular treatment and directly presented to an endovascular treatment-capable hospital is uncertain. We conducted this post hoc analysis of a randomized trial (DIRECT-MT [Direct Intraarterial Thrombectomy in Order to Revascularize Acute Ischemic Stroke Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals: A Multicenter Randomized Clinical Trial]) to explore the association of intravenous alteplase, early (preendovascular treatment) reperfusion, and clinical outcome and to determine factors which may modify alteplase treatment effect on early reperfusion. Methods: In this post hoc analysis of the DIRECT-MT randomized trial comparing intravenous alteplase before endovascular treatment versus endovascular treatment only, 623 of 656 randomized patients, with adequate angiographic evaluation for early reperfusion assessment, were included. The association of intravenous alteplase and early reperfusion (defined as expanded Thrombolysis in Cerebral Infarction score ≥2a on angiogram) was assessed using unadjusted comparisons and multivariable logistic regression. Results: Among 623 patients included (317 received intravenous alteplase and 306 did not), early reperfusion occurred in 91 (15%) patients and was associated with better functional outcome (modified Rankin Scale score, 0–2 of 49/91 [54%] versus 178/531 [34%]; adjusted odds ratio, 1.92 [95% CI, 1.15–3.21]; P <0.001). Intravenous alteplase was independently associated with early reperfusion (59/317 [19%] versus 32/306 [10%]; adjusted odds ratio, 2.06 [95% CI, 1.27–3.33]; P =0.003), and the alteplase effect was modified by time from randomization to groin puncture (dichotomized by median, ≤33 minutes; adjusted odds ratio, 1.06 [95% CI, 0.53–2.10] versus >33 minutes; adjusted odds ratio, 4.07 [95% CI, 1.86–8.86]; P interaction =0.012). ConclusionS: For patients with large vessel occlusion directly presenting to an endovascular treatment–capable hospital, intravenous alteplase increases early reperfusion when endovascular treatment gets delayed more than approximately half an hour. Thus, intravenous alteplase should be considered if endovascular treatment delays are anticipated by the treating medical team. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03469206.

peripheral vascular disease,clinical neurology
Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice

Steven J. Warach,Adrienne N. Dula,Truman J. Milling,Samantha Miller,Leigh Allen,Nathan D. Zuck,Collin Miller,Christine A. Jesser,Lotika R. Misra,Jefferson T. Miley,Manzure Mawla,Ming-Chieh Ding,John A. Bertelson,Annie Y. Tsui,John R. Jefferson,Holly M. Davison,Darshan N. Shah,Kent T. Ellington,Matthew M. Padrick,Alan S. Nova,Vivek R. Krishna,Lisa A. Davis,David Paydarfar

DOI: https://doi.org/10.1161/STROKEAHA.122.038950

IF: 10.17

2022-09-25

Stroke

Abstract:Stroke, Ahead of Print. Background:A 10-hospital regional network transitioned to tenecteplase as the standard of care stroke thrombolytic in September 2019 because of potential workflow advantages and reported noninferior clinical outcomes relative to alteplase in meta-analyses of randomized trials. We assessed whether tenecteplase use in routine clinical practice reduced thrombolytic workflow times with noninferior clinical outcomes.Methods:We designed a prospective registry-based observational, sequential cohort comparison of tenecteplase- (n=234) to alteplase-treated (n=354) stroke patients. We hypothesized: (1) an increase in the proportion of patients meeting target times for target door-to-needle time and transfer door-in-door-out time, and (2) noninferior favorable (discharge to home with independent ambulation) and unfavorable (symptomatic intracranial hemorrhage, in-hospital mortality or discharge to hospice) in the tenecteplase group. Total hospital cost associated with each treatment was also compared.Results:Target door-to-needle time within 45 minutes for all patients was superior for tenecteplase, 41% versus 29%; adjusted odds ratio, 1.85 (95% CI, 1.27–2.71);P=0.001; 58% versus 41% by Get With The Guidelines criteria. Target door-in-door-out time within 90 minutes was superior for tenecteplase 37% (15/43) versus 14% (9/65); adjusted odds ratio, 3.62 (95% CI, 1.30–10.74);P=0.02. Favorable outcome for tenecteplase fell within the 6.5% noninferiority margin; adjusted odds ratio, 1.26 (95% CI, 0.89–1.80). Unfavorable outcome was less for tenecteplase, 7.3% versus 11.9%, adjusted odds ratio, 0.77 (95% CI, 0.42–1.37) but did not fall within the prespecified 1% noninferior boundary. Net benefit (%favorable–%unfavorable) was greater for the tenecteplase sample: 37% versus 27%.P=0.02. Median cost per hospital encounter was less for tenecteplase cases ( 15 841;P<0.001).Conclusions:Switching to tenecteplase in routine clinical practice in a 10-hospital network was associated with shorter door-to-needle time and door-in-door-out times, noninferior favorable clinical outcomes at discharge, and reduced hospital costs. Evaluation in larger, multicenter cohorts is recommended to determine if these observations generalize.

peripheral vascular disease,clinical neurology
Abstract TMP86: Effects of Tenecteplase versus Alteplase in Stroke Patients With Large Vessel Occlusions Who Achieve Full Recanalization

Aron Gedansky,Thomas Patterson,Gabor Toth

DOI: https://doi.org/10.1161/str.55.suppl_1.tmp86

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: Tenecteplase improves reperfusion and functional outcomes in stroke patients with large vessel occlusion. TNK is more specific for fibrin than TPA, however, it is unclear if this effect could increase efficacy of mechanical thrombectomy (MT). We aimed to determine if TNK is associated with higher recanalization rates and better clinical outcomes than TPA in patients who undergo MT. Methods: Electronic medical record review of acute stroke patients with LVO, age over 18 years, who received both thrombolysis with either TNK or TPA, and underwent MT at a tertiary medical center from January 2017 to April 2023 was performed. Use of TPA was converted to TNK on 1/11/2022 per hospital policy. Number of passes and time to full recanalization (defined as TICI 3) were recorded. Primary outcome was mRS at 90 days. Secondary outcomes were NIHSS at 24 hours and at discharge. Primary safety outcome was parenchymal hematoma type 2 (PH2) intracerebral hemorrhage. A t-test was used to examine association between outcomes and thrombolysis type. Fischer’s exact test was used to determine differences in recanalization and hemorrhage rates. Results: Of the 284 patients included, 213 received TPA and 71 received TNK. Mean age was 68, and 50.0% were females. Forty-three patients (60.6%) who received TNK, and 96 patients (45.1%) who received TPA achieved TICI 3 score (P=0.028). There was no difference in time to recanalization (38.5 min versus 32 min, p=0.872), median number of passes (1 versus 1, p=0.934), median 90-day mRS (2 versus 1.5, p=0.434), or the rate of PH2 hemorrhage (0% versus 2.3%, p=0.336) for TNK vs TPA in patients with TICI 3 recanalization. Median NIHSS at presentation (18.0 versus 16.0, p=0.398), at 24 hours (8.0 versus 7.0, p=0.406), and at discharge (3.0 versus 4.0, p=0.383) were similar for all patients receiving TNK and TPA, respectively. Conclusions: In our retrospective analysis, TNK showed a higher rate of TICI 3 recanalization for patients with LVO, who both received thrombolysis and underwent MT. There was no difference between TNK and TPA for number of passes, time to recanalization, parenchymal hematoma rate, and clinical outcomes in patients who achieved TICI 3. Overall clinical outcomes were also similar, irrespective of recanalization grade.

peripheral vascular disease,clinical neurology
Mathematical Modeling and Optimization Studies on Development of Fuel Cells for Multifarious Applications

A. Shukla

2010-05-12

Abstract:Abstract : Direct borohydride fuel cells (DBFCs) are among the most energy dense power sources projected for futuristic portable applications. In this project, authors developed a three-dimensional, multicomponent steady-state model for liquid-feed solid polymer electrolyte DBFCs. These fuel cells use sodium borohydride (NaBH4) in alkaline media as fuel and acidified hydrogen peroxide (H2O2) as oxidant. The model employs implementation of phenomenological transport equations for the catalyst layers, diffusion layers and the polymer electrolyte membrane for a liquid feed DBFC. Diffusion of reactants within and between the pores is accounted under the framework of macrohomogeneous porous electrode theory. The kinetic treatment considered for porous structures of the catalyst layers is of Butler-Volmer type. Numerical solutions are achieved after coupling electrochemical reaction kinetics and transport mechanisms in the conservation laws, which explicitly include the effect of concentration and pressure gradients on cell polarization within the bulk catalyst layers. To understand fully the role of model parameters in simulating the performance of the DBFC, its parametric study is also carried out. A study has also been carried out for the experimental validation of the model.
Arterial Recanalization During Interhospital Transfer for Thrombectomy

Pierre Seners,Anke Wouters,Adrien Ter Schiphorst,Nicole Yuen,Michael Mlynash,Caroline Arquizan,Jeremy J. Heit,Stephanie Kemp,Soren Christensen,Denis Sablot,Anne Wacongne,Thibault Lalu,Vincent Costalat,Maarten G. Lansberg,Gregory W. Albers

DOI: https://doi.org/10.1161/strokeaha.124.046694

IF: 10.17

2024-05-18

Stroke

Abstract:Stroke, Ahead of Print. BACKGROUND:Patients with acute ischemic stroke harboring a large vessel occlusion admitted to nonendovascular-capable centers often require interhospital transfer for thrombectomy. We evaluated the incidence and predictors of arterial recanalization during transfer, as well as the relationship between interhospital recanalization and clinical outcomes.METHODS:We analyzed data from 2 cohorts of patients with an anterior circulation large vessel occlusion transferred for consideration of thrombectomy to a comprehensive center, with arterial imaging at the referring hospital and on comprehensive stroke center arrival. Interhospital recanalization was determined by comparison of the baseline and posttransfer arterial imaging and was defined as revised arterial occlusive lesion (rAOL) score 2b to 3. Pretransfer variables independently associated with interhospital recanalization were studied using multivariable logistic regression analysis.RESULTS:Of the 520 included patients (Montpellier, France, n=237; Stanford, United States, n=283), 111 (21%) experienced interhospital recanalization (partial [rAOL=2b] in 77% and complete [rAOL=3] in 23%). Pretransfer variables independently associated with recanalization were intravenous thrombolysis (adjusted odds ratio, 6.8 [95% CI, 4.0–11.6]), more distal occlusions (intracranial carotid occlusion as reference: adjusted odds ratio, 2.0 [95% CI, 0.9–4.5] for proximal first segment of the middle cerebral artery, 5.1 [95% CI, 2.3–11.5] for distal first segment of the middle cerebral artery, and 5.0 [95% CI, 2.1–11.8] for second segment of the middle cerebral artery), and smaller clot burden (clot burden score 0–4 as reference: adjusted odds ratio, 3.4 [95% CI, 1.5–7.6] for 5–7 and 5.6 [95% CI, 2.4–12.7] for 8–9). Recanalization on arrival at the comprehensive center was associated with less interhospital infarct growth (rAOL, 0–2a: 11.6 mL; rAOL, 2b: 2.2 mL; rAOL, 3: 0.6 mL;Ptrend<0.001) and greater interhospital National Institutes of Health Stroke Scale score improvement (0 versus −5 versus −6;Ptrend<0.001). Interhospital recanalization was associated with reduced 3-month disability (adjusted common odds ratio, 2.51 [95% CI, 1.68–3.77]) with greater benefit from complete than partial recanalization.CONCLUSIONS:Recanalization is frequently observed during interhospital transfer for thrombectomy and is strongly associated with favorable outcomes, even when partial. Broadening thrombolysis indications in primary centers, and developing therapies that increase recanalization during transfer, will likely improve clinical outcomes.

peripheral vascular disease,clinical neurology
Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial

Nishita Singh,Mohammed A. Almekhlafi,Fouzi Bala,Ayoola Ademola,Shelagh B. Coutts,Yan Deschaintre,Houman Khosravani,Brian Buck,Ramana Appireddy,Francois Moreau,Gord Gubitz,Aleksander Tkach,Luciana Catanese,Dar Dowlatshahi,George Medvedev,Jennifer Mandzia,Aleksandra Pikula,Jai Jai Shankar,Esseeddeegg Ghrooda,Alexandre Y. Poppe,Heather Williams,Thalia S. Field,Alejandro Manosalva,Muzaffar M. Siddiqui,Atif Zafar,Oje Imoukhoude,Gary Hunter,Michel Shamy,Andrew M. Demchuk,Brian L. Claggett,Michael D. Hill,Tolulope T. Sajobi,Richard H. Swartz,Bijoy K. Menon

DOI: https://doi.org/10.1161/strokeaha.123.044267

IF: 10.17

2023-10-08

Stroke

Abstract:Stroke, Ahead of Print. BACKGROUND:The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset. The effect of time to treatment on clinical outcomes with alteplase is well known; however, the nature of this relationship is yet to be described with tenecteplase. We assessed whether the association of time to thrombolysis treatment with clinical outcomes in patients with acute ischemic stroke differs by whether they receive intravenous tenecteplase versus alteplase.METHODS:Patients included were from AcT, a pragmatic, registry-linked, phase 3 randomized controlled trial comparing intravenous tenecteplase to alteplase in patients with acute ischemic stroke. Eligible patients were >18 years old, with disabling neurological deficits, presenting within 4.5 hours of symptom onset, and eligible for thrombolysis. Primary outcome was modified Rankin Scale score 0 to 1 at 90 days. Safety outcomes included 24-hour symptomatic intracerebral hemorrhage and 90-day mortality rates. Mixed-effects logistic regression was used to assess the following: (a) the association of stroke symptom onset to needle time; (b) door (hospital arrival) to needle time with outcomes; and (c) if these associations were modified by type of thrombolytic administered (tenecteplase versus alteplase), after adjusting for age, sex, baseline stroke severity, and site of intracranial occlusion.RESULTS:Of the 1538 patients included in this analysis, 1146 (74.5%; 591 tenecteplase and 555 alteplase) presented within 3 hours versus 392 (25.5%; 196: TNK and 196 alteplase) who presented within 3 to 4.5 hours of symptom onset. Baseline patient characteristics in the 0 to 3 hours versus 3- to 4.5-hour time window were similar, except patients in the 3- to 4.5-hour window had lower median baseline National Institutes of Health Stroke Severity Scale (10 versus 7, respectively) and lower proportion of patients with large vessel occlusion on baseline CT angiography (26.9% versus 18.7%, respectively). Type of thrombolytic agent (tenecteplase versus alteplase) did not modify the association between continuous onset to needle time (Pinteraction=0.161) or door-to-needle time (Pinteraction=0.972) and primary clinical outcome. Irrespective of the thrombolytic agent used, each 30-minute reduction in onset to needle time was associated with a 1.8% increase while every 10 minutes reduction in door-to-needle time was associated with a 0.2% increase in the probability of achieving 90-day modified Rankin Scale score 0 to 1, respectively.CONCLUSIONS:The effect of time to tenecteplase administration on clinical outcomes is like that of alteplase, with faster administration resulting in better clinical outcomes.REGISTRATION:URL:https://classic.clinicaltrials.gov; Unique identifier: NCT03889249.

peripheral vascular disease,clinical neurology
Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial

Fouzi Bala,Nishita Singh,Katrina Ignacio,Ibrahim Alhabli,Ayoola Ademola,Anas Alrohimi,Houman Khosravani,Aleksander Tkach,Luciana Catanese,Dariush Dowlatshahi,Thalia Field,Gary Hunter,Faysal Benali,MacKenzie Horn,Andrew Demchuk,Michael Hill,Tolulope Sajobi,Brian Buck,Richard Swartz,Mohammed Almekhlafi,Bijoy K Menon

DOI: https://doi.org/10.5853/jos.2023.03713

Abstract:Background and purpose: The safety and efficacy of tenecteplase in patients with ischemic stroke due to medium vessel occlusion (MeVO) are not well studied. We aimed to compare tenecteplase with alteplase in stroke due to MeVO. Methods: Patients with baseline M2-middle cerebral artery (MCA), M3/M4-MCA, P2/P3/P4-posterior cerebral artery (PCA), A2/A3/A4-anterior cerebral artery (ACA) occlusions from the Alteplase Compared to Tenecteplase (AcT) trial were included. Primary outcome was the proportion of 90-day modified Rankin Scale (mRS) 0-1. Secondary outcomes were 90-day mRS 0-2, ordinal mRS, mortality, quality of life measures (EuroQol 5-Dimension 5-Level, EuroQol visual analog scale), and symptomatic intracerebral hemorrhage (sICH). Initial and final successful reperfusion were reported in patients undergoing endovascular thrombectomy (EVT). Results: Among 1,558 patients with available baseline computed tomography angiography; 455 (29.2%) had MeVO of which 27.5% (125/455) were proximal M2; 16.3% (74/455) were distal M2; 35.2% (160/455) were M3/M4; 7.5% (34/455) were A2/A3/A4; and 13.6% (62/455) were P2/P3/P4 occlusions. EVT was performed in 87/455 (19.1%) patients. mRS 0-1 at 90 days was achieved in 37.9% in the tenecteplase versus 34.7% in the alteplase group (adjusted risk ratio [aRR] 1.07; 95% confidence interval [CI] 0.91-1.25). Rates of 90-day mRS 0-2, sICH, and mortality were similar in both groups. No statistical difference was noted in initial successful reperfusion rates (13.0% vs. 7.5%) among the 87 patients who underwent endovascular thrombectomy. However, final successful reperfusion was higher in the tenecteplase group (71.7% vs. 60.0%, aRR 1.29, 95% CI 1.04-1.61). Conclusion: Intravenous tenecteplase had comparable safety, functional outcomes and quality of life compared to intravenous alteplase among patients with MeVO. Among those treated with EVT, tenecteplase was associated with higher successful reperfusion rates than alteplase.
Abstract WP20: Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase versus Tenecteplase Real-World Experience

Courtney Hill,Rime Ezzeldin,Eryn Percenti,Ali Kerro,Adam Delora,Juan Santos,Hamzah Saei,Lisa Greco,Mohammad Elghanem,Yazan J Alderazi,Yana Kim,Cathleen M Poitevint,Osman Mir,Mohamad Ezzeldin

DOI: https://doi.org/10.1161/str.55.suppl_1.wp20

IF: 10.17

2024-02-03

Stroke

Abstract:Stroke, Volume 55, Issue Suppl_1, Page AWP20-AWP20, February 1, 2024. Importance:Tenecteplase use is more prevalent as the thrombolytic drug of choice for acute ischemic stroke, with results demonstrating its non-inferiority compared to alteplase. However, there is conflicting data regarding intracranial hemorrhage risk.Objective:To determine the rate of symptomatic intracranial hemorrhage in ischemic stroke patients after thrombolysis with either tenecteplase or alteplase.Design:Retrospective cohort study.Setting:15 Texas stroke centers.Participants:431 patients that were eligible for thrombolytic therapy, and received either tenecteplase or alteplase.Exposure:Data was collected 90 days before and after the stroke center changed from alteplase to tenecteplase.Main Outcomes:Primary endpoint was to compare the incidence of sICH according to SITS-MOST/ECASS-3 criteria in the alteplase and tenecteplase groups. Secondary endpoint included the radiographic pattern of hemorrhagic conversion according to the Heidelberg bleeding classification (HBC).Results:Median age was 62.94 for alteplase and 64.45 for tenecteplase, females represented half of each cohort:110 for alteplase and 117 for tenecteplase. Half of patients received alteplase (n=216), 174 (81%) received alteplase within 3 hours versus 176 (82%) for tenecteplase. Endovascular thrombectomy was attempted in 34 patients (15%) receiving alteplase versus 26 patients (12%) receiving tenecteplase. 7 patients in the alteplase group (3.2%) and 14 (6.5%) in the tenecteplase group had sICH, with an odds ratio of 1.44 (95% CI 0.60-3.43; P=0.41). A higher NIHSS score on arrival (1.06; 95% CI 1.0004-1.131; P=0.04) was a statistically significant predictor of sICH. A two-sample proportion test on tenecteplase produced a statistically significant increase in HBC class 3 (P=0.040) over alteplase.Conclusions and Relevance:An increased rate of sICH was observed with a statistically significant increase in HBC class 3 with tenecteplase administration compared to alteplase. Suggested mechanisms of bleeding are hemorrhagic conversion in clinically silent infarcts and contusions underlying the lesions. This suggests a potential need to reevaluate the criteria for tenecteplase administration. Larger studies are required to confirm this data.

peripheral vascular disease,clinical neurology
Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis

Yu Yao,Yuefei Wu,Xiaoqin Zhang,Chang Liu,Lingling Cai,Yisha Ying,Jianhong Yang

DOI: https://doi.org/10.3389/fneur.2024.1386386

IF: 3.4

2024-04-20

Frontiers in Neurology

Abstract:Background: This retrospective observational cohort study aimed to evaluate whether tenecteplase's use for acute ischemic stroke (AIS) has time management advantages and clinical benefits. Methods: 144 AIS patients treated with alteplase and 120 with tenecteplase were included. We compared baseline clinical characteristics, key reperfusion therapy time indices [onset-to-treatment time (OTT), door-to-needle time (DNT), and door-to-puncture time (DPT)] and clinical outcomes (24-h post-thrombolysis NIHSS improvement, and intracranial hemorrhage incidence) between the groups using univariate analysis. We assessed hospital stay durations and used binary logistic regression to examine tenecteplase's association with DNT and DPT target times, NIHSS improvement, and intracranial hemorrhage. Results: Baseline characteristics showed no significant differences except hyperlipidemia and atrial fibrillation. OTT (133 vs. 163.72, p = 0.001), DNT (36.5 vs. 50, p < 0.001) and DPT (117 vs. 193, p = 0.002) were significantly faster in the tenecteplase group. The rates of DNT ≤ 45 min (65.83% vs. 40.44%, p < 0.001) and DPT ≤ 120 min (59.09% vs. 13.79%, p = 0.001) were significantly higher in the tenecteplase group. Tenecteplase was an independent predictor of achieving target DNT (OR 2.951, 95% CI 1.732–5.030; p < 0.001) and DPT (OR 7.867, 95% CI 1.290–47.991; p = 0.025). Clinically, the proportion NIHSS improvement 24 h post-thrombolysis was higher in the tenecteplase group (64.17% vs. 50%, p = 0.024). No significant differences were observed in symptomatic intracranial hemorrhage (sICH) or any intracranial hemorrhage (ICH). Patients receiving tenecteplase had shorter hospital stays (6 vs. 8 days, p < 0.001). Tenecteplase was an independent predictor of NIHSS improvement at 24 h (OR 1.715, 95% CI 1.011–2.908; p = 0.045). There was no significant association between thrombolytic choice and sICH or any ICH. Conclusion: Tenecteplase significantly reduced DNT and DPT. It was associated with early neurological function improvement (at 24 h), without compromising safety compared to alteplase. The findings support tenecteplase's application in AIS.

neurosciences,clinical neurology
Intravenous thrombolysis with tenecteplase versus alteplase combined with endovascular treatment of anterior circulation tandem occlusions: A pooled analysis of ETIS and TETRIS

Gaultier Marnat,Bertrand Lapergue,Benjamin Gory,Maeva Kyheng,Julien Labreuche,Guillaume Turc,Stephanze Olindo,Igor Sibon,Jildaz Caroff,Didier Smadja,Nicolas Chausson,Frederic Clarençon,Pierre Seners,Romain Bourcier,Raoul Pop,Jean-Marc Olivot,Mikael Mazighi,Solène Moulin,Kevin Janot,Christophe Cognard,Sonia Alamowitch,Gaspard Gerschenfeld

DOI: https://doi.org/10.1177/23969873231206894

IF: 6.1

2023-10-15

European Stroke Journal

Abstract:European Stroke Journal, Ahead of Print. Background:Tandem occlusions are a singular large vessel occlusion entity involving specific endovascular and perioperative antithrombotic management. In this context, data on safety and efficacy of prior intravenous thrombolysis (IVT) with tenecteplase is scarce. We aimed to compare IVT with tenecteplase or alteplase in patients with acute tandem occlusions intended for endovascular treatment.Patients and methods:A retrospective pooled analysis of two large observational registries (ETIS (Endovascular Treatment of Ischemic Stroke) and TETRIS (Tenecteplase Treatment in Ischemic Stroke)) was performed on consecutive patients presenting with anterior circulation tandem occlusion treated with IVT using either alteplase (ETIS) or tenecteplase (TETRIS) followed by endovascular treatment between January 2015 and June 2022. Sensitivity analyses on atherosclerosis related tandem occlusions and on patient treated with emergent carotid stenting were conducted. Propensity score overlap weighting analyses were performed.Results:We analyzed 753 patients: 124 in the tenecteplase and 629 in the alteplase group. The overall odds of favorable outcome (3-month modified Rankin score 0–2) were comparable between both groups (49.4% vs 47.1%; OR = 1.10, 95%CI 0.85–1.41). Early recanalization, final successful recanalization and mortality favored the use of tenecteplase. The occurrence of any intracranial hemorrhage (ICH) was more frequent after tenecteplase use (OR = 2.24; 95%CI 1.75–2.86). However, risks of symptomatic ICH and parenchymal hematoma remained similar. In atherosclerotic tandems, favorable outcome, mortality, parenchymal hematoma, early recanalization, and final successful recanalization favored the tenecteplase group. In the carotid stenting subgroup, PH were less frequent in the tenecteplase group (OR = 0.18; 95%CI 0.05–0.69).Conclusion:In patients with tandem occlusions, IVT with tenecteplase seemed reasonably safe in particular with increased early recanalization rates. These findings remain preliminary and should be further confirmed in randomized trials.
Abstract TP149: Pretreatment Parameters Predicting Excellent Recanalization of Large Vessel Occlusion in Patients With Acute Ischemic Stroke

Manisha Koneru,Meisam Hoseinyazdi,Cynthia Greene,Adam A Dmytriw,Adrien Guenego,Jeremy J Heit,Greg W Albers,Kambiz Nael,Risheng Xu,Victor C Urrutia,Elisabeth B Marsh,Richard Leigh,Rafael H Llinas,Argye E Hillis,Vivek Yedavalli

DOI: https://doi.org/10.1161/str.55.suppl_1.tp149

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: In large vessel occlusion (LVO) ischemic stroke patients, better functional outcomes are associated with achieving modified thrombolysis in cerebral infarction (mTICI) score 2C/3 in comparison to 2B. The purpose of this study was to identify pretreatment and interventional predictors of mTICI 2C/3 over 2B reperfusion in patients with LVOs treated successfully with thrombectomy. Methods: Data from two comprehensive stroke centers between 2019-2023 were retrospectively reviewed for LVO acute ischemic stroke patients treated successfully (mTICI 2B/2C/3) with thrombectomy. Primary outcome measure was achieving mTICI 2C/3 (i.e., excellent) revascularization. Demographic variables, CT perfusion parameters, and intervention-related parameters were evaluated as univariate regressors of primary outcome. Significant univariate predictors were included in a forward stepwise multivariate logistic regression, and adjusted odds ratios (aOR) were reported. Results: Of 149 patients, the median age was 70 years old (IQR: 65-78.5), and 57.7% were female. Multivariate logistic regression analyses (AUC = 0.79, 95% CI: 0.68-0.86, p = 0.7 (aOR 3.75, p = 0.007), and thrombectomy with aspiration alone (aOR 2.89, p = 0.012). Conclusions: Robust collateral status (as represented by CBV index), absence of diabetes mellitus, no prior stroke history, lower initial stroke severity, and aspiration thrombectomy were associated with increased likelihood of excellent recanalization amongst technically successfully revascularized LVO stroke patients. Preventative comorbidity management, collateral status on imaging, and thrombectomy technique may optimize chances for excellent recanalization.

peripheral vascular disease,clinical neurology
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke (AcT) Trial: Protocol for a Pragmatic Registry linked Randomized Clinical Trial

Tolulope Sajobi,Nishita Singh,Mohammed A. Almekhlafi,Brian Buck,Ayoola Ademola,Shelagh B. Coutts,Yan Deschaintre,Houman Khosravani,Ramana Appireddy,Francois Moreau,Stephen Phillips,Gord Gubitz,Aleksander Tkach,Luciana Catanese,Dar Dowlatshahi,George Medvedev,Jennifer Mandzia,Aleksandra Pikula,J.J. Shankar,Heather Williams,Thalia S. Field,Alejandro Manosalva,Muzaffar Siddiqui,Atif Zafar,Oje Imoukhoude,Gary Hunter,Arshia Sehgal,Qiao Zhang,Craig Doram,Michael D. Hill,Michel Shamy,Carol Kenney,Richard H. Swartz,Bijoy K. Menon

DOI: https://doi.org/10.1161/svin.121.000447

2022-05-06

Stroke: Vascular and Interventional Neurology

Abstract:Background : Intravenous thrombolysis with alteplase is widely used in acute ischemic stroke patients presenting early after symptom onset. Recent phase II trials have suggested that intravenous tenecteplase may be safer and associated with higher early reperfusion rates as compared to alteplase. This study investigates whether intravenous tenecteplase is non‐inferior to intravenous alteplase for the treatment of acute ischemic stroke. Methods : This is a pragmatic, registry‐linked, prospective, randomized (1:1) controlled, open‐label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non‐inferior to intravenous alteplase (0.9 mg/kg body weight, max dose 90 mg) in patients with acute ischemic stroke eligible for intravenous thrombolysis in clinical routine. Patients are recruited from comprehensive and primary stroke centers and enrolled using deferral of consent. The proposed sample has at least 90% power with a non‐inferiority margin of 5%, assuming incidence of 90‐day mRS 0–1 is 38% in the tenecteplase and 35% in the alteplase groups, and a loss to follow‐up rate < 5%. Results : The blinded primary endpoint is the proportion of subjects achieving a 90‐day mRS (modified Rankin scale) of 0–1. Key safety outcomes include 24‐hour symptomatic intracerebral hemorrhage and 90‐day all‐cause mortality. All serious adverse events within 24‐hour period will be reported and coded using MedDRA. Outcomes are collected either centrally (primary, key secondary and safety endpoints) or through ongoing Canadian stroke registries. The primary analysis is a simple unadjusted comparison of proportions. Conclusion : Results from the trial will provide real‐world evidence of the effectiveness of intravenous tenecteplase vs. alteplase in patients with acute ischemic stroke presenting early after stroke onset. Clinical Trial Registration: NCT03889249 https://clinicaltrials.gov/ct2/show/NCT03889249 This article is protected by copyright. All rights reserved
Tenecteplase versus alteplase before stroke thrombectomy: outcomes after system-wide transitions in Pennsylvania

Philipp Hendrix,Bradley A Gross,Sepideh Allahdadian,Georgios S Sioutas,Prateeka Koul,Antonio Corral Tarbay,Michael J Lang,Visish M Srinivasan,Alhamza R Al-Bayati,Jiang Li,Anthony Noto,Raul G Nogueira,Jan-Karl Burkhardt,Ramin Zand,Clemens M Schirmer

DOI: https://doi.org/10.1007/s00415-024-12530-x

Abstract:Introduction: United States stroke systems are increasingly transitioning from alteplase (TPA) to tenecteplase (TNK). Real-world data on the safety and effectiveness of replacing TPA with TNK before large vessel occlusion (LVO) stroke endovascular treatment (EVT) are lacking. Methods: Four Pennsylvania stroke systems transitioned from TPA to TNK during the study period 01/2020-06/2023. LVO stroke patients who received intravenous thrombolysis with TPA or TNK before EVT were reviewed. Multivariate logistic analysis was conducted adjusting for age, sex, National Institute of Health Stroke Scale (NIHSS), occlusion site, last-known-well-to-intravenous thrombolysis time, interhospital-transfer and stroke system. Results: Of 635 patients, 309 (48.7%) received TNK and 326 (51.3%) TPA prior to EVT. The site of occlusion was the M1 middle cerebral artery (MCA) (47.7%), M2 MCA (25.4%), internal carotid artery (14.0%), tandem carotid with M1 or M2 MCA (9.8%) and basilar artery (3.1%). A favorable functional outcome (90-day mRS ≤ 2) was observed in 47.6% of TNK and 49.7% of TPA patients (p = 0.132). TNK versus TPA groups had similar rates of early recanalization (11.9% vs. 8.4%, p = 0.259), successful endovascular reperfusion (93.5% vs. 89.3%, p = 0.627), symptomatic intracranial hemorrhage (3.2% vs. 3.4%, p = 0.218) and 90-day all-cause mortality (23.1% vs. 21.5%, p = 0.491). Conclusions: This U.S. multicenter real-world clinical experience demonstrated that switching from TPA to TNK before EVT for LVO stroke resulted in similar endovascular reperfusion, safety, and functional outcomes.
Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

Radhika Nair,Nishita Singh,Mahesh Kate,Negar Asdaghi,Robert Sarmiento,Fouzi Bala,Shelagh B Coutts,MacKenzie Horn,Alexandre Y Poppe,Heather Williams,Ayoola Ademola,Ibrahim Alhabli,Faysal Benali,Houman Khosravani,Gary Hunter,Aleksander Tkach,Herbert Alejandro Manosalva Alzate,Aleksandra Pikula,Thalia Field,Anurag Trivedi,Dar Dowlatshahi,Luciana Catanese,Ashfaq Shuaib,Andrew Demchuk,Tolulope Sajobi,Mohammed A Almekhlafi,Richard H Swartz,Bijoy Menon,Brian H Buck

DOI: https://doi.org/10.1136/svn-2023-002828

IF: 5.9

2024-01-31

Stroke and Vascular Neurology

Abstract:Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability. We compared the efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase in patients who had a minor stroke enrolled in the Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (AcT) trial. Methods The AcT trial included individuals with ischaemic stroke, aged >18 years, who were eligible for standard-of-care intravenous thrombolysis. Participants were randomly assigned 1:1 to intravenous tenecteplase (0.25 mg/kg) or alteplase (0.9 mg/kg). Patients with minor deficits pre-thrombolysis were included in this post-hoc exploratory analysis. The primary efficacy outcome was the proportion of patients with a modified Rankin Score (mRS) of 0–1 at 90–120 days. Safety outcomes included mortality and symptomatic intracranial haemorrhage (sICH). Results Of the 378 patients enrolled in AcT with an NIHSS of ≤5, the median age was 71 years, 39.7% were women; 194 (51.3%) received tenecteplase and 184 (48.7%) alteplase. The primary outcome (mRS score 0–1) occurred in 100 participants (51.8%) in the tenecteplase group and 86 (47.5 %) in the alteplase group (adjusted risk ratio (RR) 1.14 (95% CI 0.92 to 1.40)). There were no significant differences in the rates of sICH (2.9% in tenecteplase vs 3.3% in alteplase group, unadjusted RR 0.79 (0.24 to 2.54)) and death within 90 days (5.5% in tenecteplase vs 11% in alteplase group, adjusted HR 0.99 (95% CI 0.96 to 1.02)). Conclusion In this post-hoc analysis of patients with minor stroke enrolled in the AcT trial, safety and efficacy outcomes with tenecteplase 0.25 mg/kg were not different from alteplase 0.9 mg/kg.

clinical neurology
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

H. Zhong,M. May,E. Jimi,S. Ghosh

Molecules and Cells

Abstract:Homodimers of the NF-kappa B p50 subunit are transcriptionally repressive in cells, whereas they can promote transcription in vitro, suggesting that their endogenous effects are mediated by association with other factors. We now demonstrate that transcriptionally inactive nuclear NF-kappaB in resting cells consists of homodimers of either p65 or p50 complexed with the histone deacetylase HDAC-1. Only the p50-HDAC-1 complexes bind to DNA and suppress NF-kappa B-dependent gene expression in unstimulated cells. Appropriate stimulation causes nuclear localization of NF-kappa B complexes containing phosphorylated p65 that associates with CBP and displaces the p50-HDAC-1 complexes. Our results demonstrate that phosphorylation of p65 determines whether it associates with either CBP or HDAC-1, ensuring that only p65 entering the nucleus from cytoplasmic NF-kappa B:Ikappa B complexes can activate transcription.
Endovascular thrombectomy without versus with different pre-intravenous thrombolysis in acute ischemic stroke: a network meta-analysis of randomized controlled trials

Sitong Guo,Shiran Qin,Sitao Tan,Henghai Su,Xiaoyu Chen

DOI: https://doi.org/10.3389/fneur.2024.1344961

IF: 3.4

2024-01-30

Frontiers in Neurology

Abstract:Background: The current guideline recommended the use of intravenous thrombolysis (IVT) before Endovascular thrombectomy (EVT), but the effectiveness and safety of tenecteplase compare to alteplase in patients before EVT remain uncertain. Methods: We searched PubMed, Embase, Web of Science, and the Cochrane Library to identify eligible articles from inception until September 16, 2023. The primary outcome was functional independence (mRS 0–2) at 90 days. Secondary outcomes included excellent outcome (mRS 0–1) at 90 days, all-cause mortality at follow-up, successful reperfusion (TICI 2b–3) after the end of EVT, symptomatic intracranial hemorrhage (sICH) or any intracranial hemorrhage (aICH). The PROSPERO registration number is CRD42023470419. Results: Eight randomized controlled trials (RCTs) were included involving 2,836 acute ischemic stroke (AIS) patients. Compared to EVT alone, tenecteplase (0.25 mg/kg and 0.4 mg/kg) + EVT and 0.9 mg/kg alteplase + EVT were significant difference associated with higher successful reperfusion (TICI 2b–3) after the end of EVT (RR = 2.31; 95% CI 1.15–4.63; RR = 2.31; 95% CI 1.00–5.33; RR = 1.05; 95% CI 1.01–1.09). And compared to 0.25 mg/kg tenecteplase + EVT, alteplase (0.6 mg/kg and 0.9 mg/kg) + EVT were significant difference associated with lower successful reperfusion (TICI 2b–3) after the end of EVT (RR = 0.45; 95% CI 0.22–0.90; RR = 0.45; 95% CI 0.23–0.91). The risk of aICH (RR = 1.50; 95% CI 1.07–2.09) was significantly higher for 0.6 mg/kg alteplase + EVT than EVT alone. There was no significant difference in functional independence (mRS 0–2), excellent outcome (mRS 0–1), all-cause mortality or sICH among the different IVT strategies (0.25 mg/kg or 0.4 mg/kg tenecteplase and 0.6 mg/kg or 0.9 mg/kg alteplase) before EVT. Conclusion: The use of alteplase before EVT may potentially improve the successful reperfusion after EVT compared to tenecteplase. Due to the insufficient sample size, more high-quality RCTs are needed to confirm effectiveness and safety of tenecteplase compare to alteplase in patients before EVT. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42023470419.

neurosciences,clinical neurology

Distribution and diagnosis of dirofilariasis and toxocariasis in Australia.

Endovascular Thrombectomy with or Without Intravenous Alteplase in Acute Stroke

Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis

Effect of Baseline Infarct Size on Endovascular Thrombectomy with or Without Intravenous Alteplase in Stroke Patients: A Subgroup Analysis of a Randomized Trial (DIRECT-MT).

Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis

Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial

Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice

Abstract TMP86: Effects of Tenecteplase versus Alteplase in Stroke Patients With Large Vessel Occlusions Who Achieve Full Recanalization

Mathematical Modeling and Optimization Studies on Development of Fuel Cells for Multifarious Applications

Arterial Recanalization During Interhospital Transfer for Thrombectomy

Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial

Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial

Abstract WP20: Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase versus Tenecteplase Real-World Experience

Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis

Intravenous thrombolysis with tenecteplase versus alteplase combined with endovascular treatment of anterior circulation tandem occlusions: A pooled analysis of ETIS and TETRIS

Abstract TP149: Pretreatment Parameters Predicting Excellent Recanalization of Large Vessel Occlusion in Patients With Acute Ischemic Stroke

Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke (AcT) Trial: Protocol for a Pragmatic Registry linked Randomized Clinical Trial

Tenecteplase versus alteplase before stroke thrombectomy: outcomes after system-wide transitions in Pennsylvania

Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Endovascular thrombectomy without versus with different pre-intravenous thrombolysis in acute ischemic stroke: a network meta-analysis of randomized controlled trials